All Posts Tagged With: "SNY"
(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of...
(MHS) Medco Health Solutions Aids Sanofi-Aventis Study
Medco Health Solutions (MHS) and its subsidiary United BioSource Corporation (UBC) have entered into a multi-year agreement with leading pharmaceutical company Sanofi-Aventis (
28Jun2011 | vitalstocks | 0 comments | Continued(SHPGY) Shire to Produce More Replagal
UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved...
(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE:...
(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares
We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25.
Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer....
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(ABT) Abbott Labs’ Bardoxolone in Phase III Trials
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with...
(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA
Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application...
(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap
Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys...
(BMY) Bristol-Myers Squibb Compan Gets Good News
Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(MAA) Roche Holdings’ Skin Cancer Drug Impresses
Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual...
(RCI) Look to Dividends for Income
With the 10-year T-note yielding only 3.06%, those investors interested in getting income from their investments are in sort of a tough place. Dividend-paying stocks are a very good place to look for a replacement.
One thing you know for sure is that the coupon payment...
(OPTR) Optimer Pharma Beats on One-Time Gain
Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat...
(ISIS) Isis Pharmaceuticals Reported Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents.
Revenues...
(PRGO) Perrigo Cruises Past Estimates – Lifts Outlook
Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share....
(HSP) Hospira Earnings Beat The Street – Backs Outlook
Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version...
(NVS) Novartis Posts Solid First Quarter Sales
Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from...
(MRK) Five Large Cap Pharmaceuticals to Consider
The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change. The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected. Before...
(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen Idec Earnings Report Beats The Street
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based...
(BIIB) Biogen’s Oral Multiple Sclerosis Drug Impresses
Biogen (BIIB) received a boost recently with the company presenting promising top-line data on its oral multiple sclerosis candidate, BG-12. The company presented positive results on the use of BG-12 as a...
(PRGO) Perrigo Resolves Manufacturing Issues with FDA
Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the...
(SNY) Sanofi-Aventis Acquires Genzyme – Acquisition to Create New Source of Growth at Sanofi
Sanofi-Aventis (SNY) recently completed its acquisition of biotech company Genzyme Corporation. With the completion of the acquisition, Genzyme, now a wholly-owned subsidiary of Sanofi, will be Sanofi’s...
(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU
Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b...
(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on...
(SPPI) Spectrum Pharmaceuticals to Continue Cancer Study
Recently, Spectrum Pharmaceuticals Inc. (SPPI) announced that it will continue evaluating its cancer candidate belinostat based on the recommendation of the independent Data Monitoring Committee (DMC).
Spectrum...
(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid
Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote...
(JNJ) Bayer Presents Xarelto Blood Thinner Data
Recently, Germany’s Bayer (BAYRY) presented mixed data regarding its blood thinner Xarelto (rivaroxaban) for preventing venous thromboembolism (VTE) in hospitalized ill patients. Data from the late-stage study (MAGELLAN: n= 8,101) were presented by Bayer...
(OPTR) Optimer Pharmaceuticals Earns FDA Panel Nod on Dificid Drug
Optimer Pharmaceuticals Inc. (OPTR) received a major boost when an advisory panel of the US Food and Drug Administration (FDA) unanimously recommended approval of its lead pipeline candidate, Dificid (fidaxomicin),...